Qinghong Fu
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Pancreatic function and diabetes, Metabolism, Diabetes, and Cancer, Synthesis and Catalytic Reactions, Synthesis of heterocyclic compounds, HIV Research and Treatment
Most-Cited Works
- → Inhibition of Sphingosine-1-Phosphate Lyase for the Treatment of Autoimmune Disorders(2009)74 cited
- → Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus(2016)26 cited
- → 1,2,5-Thiadiazolidin-3-one 1,1 Dioxide: A Powerful Scaffold for Probing the S′ Subsites of (Chymo)trypsin-Like Serine Proteases(2001)21 cited
- → Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus(2016)12 cited
- → Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors(2009)10 cited
- → Improvement of hERG-ROMK index of spirocyclic ROMK inhibitors through scaffold optimization and incorporation of novel pharmacophores(2017)8 cited
- → A ONE-STEP PROTOCOL FOR THEN-CHLOROMETHYLATION OF HETEROCYCLIC IMIDES(2001)7 cited
- → 5-Fluorocytosine derivatives as inhibitors of deoxycytidine kinase(2009)5 cited
- → ChemInform Abstract: A One‐Step Protocol for the N‐Chloromethylation of Heterocyclic Imides(2002)